NYSE · Medical - Diagnostics & Research

Thermo Fisher Scientific Inc. (TMO) Stock

$594.00 +2.41% NYSE: TMO Healthcare

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services.

Valuation

MetricValue
Price$594.00
Market Cap$220.74B
P/E Ratio25.59
P/B Ratio3.28
P/S Ratio3.89
EPS (TTM)$17.74
52-Week High$643.99
52-Week Low$393.00
Dividend Yield0.38%

Financials & Margins

MetricValue
ROE13.52%
ROA5.00%
ROCE15.15%
Gross Margin18.20%
Operating Margin18.20%
Net Margin15.18%
Debt/Equity0.83
Current Ratio1.89

Annual Financials (USD)

Metric20212022202320242025
Revenue$39.2B$44.9B$42.9B$42.9B$44.6B
Operating Profit$10.3B$8.5B$7.4B$7.7B$8.1B
Net Profit$7.7B$7.0B$6.0B$6.3B$6.7B
EPS$19.46$17.64$15.45$16.53$17.74
Op Margin26.3%19.0%17.4%17.9%18.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$95.1B$97.2B$98.7B$97.3B$110.3B
Total Liabilities$54.1B$53.0B$51.9B$47.6B$56.8B
Cash$4.5B$8.5B$8.1B$4.0B$9.9B
Borrowings$36.3B$36.1B$36.4B$32.8B$40.9B

Latest News

Thermo Fisher Scientific Announces Quarterly Dividend Business Wire · Jul 9, 2026 On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations PR Newswire · Jul 8, 2026 Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG PR Newswire · Jul 8, 2026 Thermo Fisher (TMO) Wins FBI Approval For Rapid DNA Tool In Crime Investigations Simply Wall St. · Jul 7, 2026 Is ICLR Stock a Value Trap or Turnaround After an Earnings Reset? Zacks · Jul 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$9.5B$9.2B$8.4B$8.7B$7.8B
Investing Cash Flow$-24.5B$-4.4B$-6.6B$-7.2B$-5.6B
Financing Cash Flow$-1.9B$-3.0B$-2.9B$-3.8B$-2.9B
Net Cash Flow$-5.8B$4.0B$-440.0M$-4.1B$5.8B
Free Cash Flow$7.0B$6.9B$6.9B$7.3B$6.3B

Valuation & Return Ratios

MetricValue
PEG Ratio403.27
EV / EBITDA19.13
FCF Yield3.84%
Quick Ratio1.15
Interest Coverage5.71
Return 1Y17.65%
Return 3Y0.76%
Return 5Y7.63%

Ownership

Insiders Held0.15%
Institutions Held94.03%
Institutions Float Held94.17%
Institutional HolderSharesReport Date
Blackrock Inc.30,427,1922026-03-31
Vanguard Capital Management LLC24,280,8162026-03-31
State Street Corporation16,731,6682026-03-31
Morgan Stanley10,863,5282026-03-31
FMR, LLC10,776,4362026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAgilent Technologies, Inc. $137.39 -0.85% 25.52 $38.80B 0.59%
ABTAbbott Laboratories $108.03 +0.70% 24.70 $188.16B 2.77%
AMGNAmgen Inc. $387.64 -1.39% 23.42 $209.21B 2.82%
AZNAstraZeneca PLC $173.30 +0.48% 29.74 $134.31B 1.69%
DHRDanaher Corporation $196.55 -1.26% 33.17 $138.17B 0.75%

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Inc. is led by CEO Marc N. Casper, employs 125,000 people, headquartered in Waltham, US, publicly traded since 1980.

Thermo Fisher Scientific Inc. (TMO) stock trades at $594.00 with a market capitalization of $220.74B. The stock is valued at a price-to-earnings (P/E) ratio of 25.59, price-to-book of 3.28, price-to-sales of 3.89. Over the past 52 weeks the stock has ranged between $393.00 and $643.99, and currently trades 7.8% below its 52-week high. It pays a dividend yielding 0.38%.

On profitability, Thermo Fisher Scientific Inc. generates a return on equity (ROE) of 13.52%, above the typical market average, return on capital employed of 15.15%, an operating margin of 18.20%, a net profit margin of 15.18%.

In its most recent fiscal year, Thermo Fisher Scientific Inc. reported annual revenue of $44.6B, net profit of $6.7B, revenue has compounded at 6.7% a year over the last five years, profit at 1.1% a year.

The balance sheet shows a debt-to-equity ratio of 0.83, a current ratio of 1.89, total assets of $110.3B, $9.9B in cash and equivalents.

TMO has an average daily trading volume of 2,410,000 shares, a beta of 0.87.

Official website: www.thermofisher.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06% DHR Medical - Diagnostics & Research $196.55 -1.26%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides